Live Breaking News & Updates on அலுவலகம் ஆஃப் புற்றுநோயியல் நோய்கள்

Stay updated with breaking news from அலுவலகம் ஆஃப் புற்றுநோயியல் நோய்கள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Investegate |Apollon Formularies Announcements | Apollon Formularies: Apollon Formulations Kill TNBC Cells


Apollon Formulations Kill Triple-Negative Breast Cancer (TNBC) Cells
Apollon Formularies plc (AQSE: APOL) ( Apollon  or the  Company ), a UK based international pharmaceutical company trading on Aquis Stock Exchange, is pleased to announce that its proprietary medical cannabis formulations were successful in killing triple-negative breast cancer (TNBC) cells in 3D cell cultures in third party independent laboratory testing. This finding is in addition to the results recently announced on May 18, 2021, that Apollon formulations were successful in killing HER2+ breast cancer cells. This testing was performed under a joint testing agreement with Aion Therapeutic Inc. (CSE: AION) ( Aion ), a BC based international pharmaceutical company trading on the Canadian Securities Exchange.  ....

United Kingdom , United States , Richard Pazdur , Herberta Fritsche , Megan Ray , Paul Burke , Tim Blythe , Stephend Barnhill , Stene Jacobs , Aion Therapeutic Inc , Apollon Formularies Jamaica , Directors Of The Company , Oncology Center , Md Anderson Cancer Center , Research Development , Ai Pharmaceuticals Jamaica , Laboratory Medicine , University Of Texas , Canadian Securities Exchange , Board Of Aion Therapeutic Inc , Jamaican Cannabis Licensing Authority , Apollon Formularies Jamaica Limited , Cannabis Licensing Authority , Aquis Stock Exchange , Peterhouse Capital Limited Corporate Adviser , Office Of Oncologic Diseases ,